Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2003 1
2005 1
2006 1
2010 2
2011 1
2013 2
2014 4
2015 3
2016 11
2017 11
2018 7
2019 6
2020 4
2021 3
2022 1
Text availability
Article attribute
Article type
Publication date

Search Results

47 results
Results by year
Filters applied: . Clear all
Page 1
Targeting super-enhancer-associated oncogenes in oesophageal squamous cell carcinoma.
Jiang YY, Lin DC, Mayakonda A, Hazawa M, Ding LW, Chien WW, Xu L, Chen Y, Xiao JF, Senapedis W, Baloglu E, Kanojia D, Shang L, Xu X, Yang H, Tyner JW, Wang MR, Koeffler HP. Jiang YY, et al. Among authors: senapedis w. Gut. 2017 Aug;66(8):1358-1368. doi: 10.1136/gutjnl-2016-311818. Epub 2016 May 10. Gut. 2017. PMID: 27196599 Free PMC article.
PAK4 inhibition improves PD-1 blockade immunotherapy.
Abril-Rodriguez G, Torrejon DY, Liu W, Zaretsky JM, Nowicki TS, Tsoi J, Puig-Saus C, Baselga-Carretero I, Medina E, Quist MJ, Garcia AJ, Senapedis W, Baloglu E, Kalbasi A, Cheung-Lau G, Berent-Maoz B, Comin-Anduix B, Hu-Lieskovan S, Wang CY, Grasso CS, Ribas A. Abril-Rodriguez G, et al. Among authors: senapedis w. Nat Cancer. 2020;1(1):46-58. doi: 10.1038/s43018-019-0003-0. Epub 2019 Dec 9. Nat Cancer. 2020. PMID: 34368780 Free PMC article.
Therapeutic Potential of Targeting PAK Signaling.
Senapedis W, Crochiere M, Baloglu E, Landesman Y. Senapedis W, et al. Anticancer Agents Med Chem. 2016;16(1):75-88. doi: 10.2174/1871520615666150617111414. Anticancer Agents Med Chem. 2016. PMID: 26081410 Review.
PAK4-NAMPT Dual Inhibition Sensitizes Pancreatic Neuroendocrine Tumors to Everolimus.
Mpilla GB, Uddin MH, Al-Hallak MN, Aboukameel A, Li Y, Kim SH, Beydoun R, Dyson G, Baloglu E, Senapedis WT, Landesman Y, Wagner KU, Viola NT, El-Rayes BF, Philip PA, Mohammad RM, Azmi AS. Mpilla GB, et al. Among authors: senapedis wt. Mol Cancer Ther. 2021 Oct;20(10):1836-1845. doi: 10.1158/1535-7163.MCT-20-1105. Epub 2021 Jul 12. Mol Cancer Ther. 2021. PMID: 34253597 Free PMC article.
Nucleo-cytoplasmic transport as a therapeutic target of cancer.
Gravina GL, Senapedis W, McCauley D, Baloglu E, Shacham S, Festuccia C. Gravina GL, et al. Among authors: senapedis w. J Hematol Oncol. 2014 Dec 5;7:85. doi: 10.1186/s13045-014-0085-1. J Hematol Oncol. 2014. PMID: 25476752 Free PMC article. Review.
Publisher Correction: PAK4 inhibition improves PD-1 blockade immunotherapy.
Abril-Rodriguez G, Torrejon DY, Liu W, Zaretsky JM, Nowicki TS, Tsoi J, Puig-Saus C, Baselga-Carretero I, Medina E, Quist MJ, Garcia AJ, Senapedis W, Baloglu E, Kalbasi A, Cheung-Lau G, Berent-Maoz B, Comin-Anduix B, Hu-Lieskovan S, Wang CY, Grasso CS, Ribas A. Abril-Rodriguez G, et al. Among authors: senapedis w. Nat Cancer. 2020 Feb;1(2):264. doi: 10.1038/s43018-020-0025-7. Nat Cancer. 2020. PMID: 35122015 Free article. No abstract available.
Targeting Nuclear Exporter Protein XPO1/CRM1 in Gastric Cancer.
Sexton R, Mahdi Z, Chaudhury R, Beydoun R, Aboukameel A, Khan HY, Baloglu E, Senapedis W, Landesman Y, Tesfaye A, Kim S, Philip PA, Azmi AS. Sexton R, et al. Among authors: senapedis w. Int J Mol Sci. 2019 Sep 28;20(19):4826. doi: 10.3390/ijms20194826. Int J Mol Sci. 2019. PMID: 31569391 Free PMC article.
Selective targeting of NAMPT by KPT-9274 in acute myeloid leukemia.
Mitchell SR, Larkin K, Grieselhuber NR, Lai TH, Cannon M, Orwick S, Sharma P, Asemelash Y, Zhang P, Goettl VM, Beaver L, Mims A, Puduvalli VK, Blachly JS, Lehman A, Harrington B, Henderson S, Breitbach JT, Williams KE, Dong S, Baloglu E, Senapedis W, Kirschner K, Sampath D, Lapalombella R, Byrd JC. Mitchell SR, et al. Among authors: senapedis w. Blood Adv. 2019 Feb 12;3(3):242-255. doi: 10.1182/bloodadvances.2018024182. Blood Adv. 2019. PMID: 30692102 Free PMC article.
47 results